Clinical Trial Update: Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants [Phase 2, Phase 3]

View source ↗

Summary

A two-part Phase 2/Phase 3 study evaluated pharmacokinetics, safety, and antiviral activity of elvitegravir with a protease inhibitor/ritonavir background regim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infections

Drugs mentioned

• elvitegravir (elvitegravir)

Snippet

Sponsor: Gilead Sciences | Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2018-07-11